About the Editors

Antonino Carbone

Antonino Carbone served as Chairman of the Department of Pathology and Laboratory Medicine of the Istituto Nazionale dei Tumori – Milan, Italy until 2009. He is the Chairman of the Department of Pathology of the CRO, Istituto Nazionale Tumori - Aviano, and Pordenone Hospital, Italy. He is internationally recognized for his diagnostic expertise and for his many scholarly accomplishments in hematopathology. He is actively involved in the writing group of the WHO IARC Monograph Working Group on Biological Agents and Cancer, and is Chairman of the Italian TNM Staging Committee of the Union for International Cancer Control. He has published more than 700 scientific papers, primarily in hematopathology and viral carcinogenesis, in international peer-reviewed journals (h-index score: 80, Google Scholar database).

Anas Younes

As a Medical Oncologist and Chief of Memorial Sloan-Kettering's Lymphoma Service, Anas Younes works with his clinical and basic-science colleagues to accelerate the translation of recent scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphoma. He joined Memorial Sloan-Kettering in 2013 with two decades of experience in treating and managing people with lymphoma, and with an extensive background in translational scientific research. He is particularly interested in developing novel targeted therapies and linking them to biomarkers (early markers) that can help match patients with the most effective and minimally toxic medicines. He has served as the principal investigator of more than 60 clinical trials in patients with Hodgkin and non-Hodgkin lymphoma, including national and international multicenter studies. He has led the efforts of developing the first US FDA-approved targeted drug for the treatment of Hodgkin lymphoma in more than three decades (brentuximab vedotin). Nationally, he have led a National Cancer Institute-funded Specialized Programs of Research Excellence (SPORes) in lymphoma focused on developing novel treatment strategies for Hodgkin and non-Hodgkin lymphoma. He also serves on the Scientific Advisory Board of the Lymphoma Research Foundation, and is a member of the National Cancer Institute Lymphoma Steering Committee. He actively posts on social media about clinical trials, news stories, scientific publications and medical advances. You can follow him on Twitter and like his page on Facebook to stay connected.

For reprint orders, please contact: reprints@futuremedicine.com

Foreword

Antonino Carbone & Anas Younes

At least initially, tumor development and cell growth largely depend on external signals from the microenvironment, including viral antigens and cell–cell interactions [1]. Inflammatory cells and soluble mediators, in other words, cytokines and chemokines are the main microenvironmental factors that are involved in tumor cell migration and invasion, disease progression and angiogenesis [2]. Beyond the involved abnormalities, however, the relationships between lymphomas and their microenvironment appear to follow some major pathogenetic patterns: an independent, largely autonomous pattern (a typical example is Burkitt lymphoma), dependent on deregulated interactions pattern (a typical example is classic Hodgkin lymphoma) and dependent on regulated coexistence pattern (typical examples are HCV-associated marginal zone lymphomas and mucosa-associated lymphoid tissue lymphomas) [3].

In this book, chapters by distinguished authors from international academic institutions and cancer research centers highlight the relevant role of the tumor microenvironment that has recently emerged in hematolymphoid malignancies and suggest new ideas and targets for treatment.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

References

1. Carbone A, Cesarman E, Spina M, Ghoghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. *Blood* 113, 1213–1224 (2009).
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 454, 436–444 (2008).
3. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. *Blood* 114, 3367–3375 (2009).